Versor Investments LP Grows Stock Holdings in Sotera Health Company $SHC

Versor Investments LP raised its position in shares of Sotera Health Company (NASDAQ:SHCFree Report) by 233.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 46,700 shares of the company’s stock after buying an additional 32,700 shares during the quarter. Versor Investments LP’s holdings in Sotera Health were worth $824,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. True Wealth Design LLC lifted its position in shares of Sotera Health by 389.3% during the fourth quarter. True Wealth Design LLC now owns 1,830 shares of the company’s stock valued at $32,000 after buying an additional 1,456 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Sotera Health by 831.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock valued at $37,000 after buying an additional 2,935 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Sotera Health by 117.6% during the third quarter. Versant Capital Management Inc now owns 2,535 shares of the company’s stock valued at $40,000 after buying an additional 1,370 shares during the last quarter. Fairway Wealth LLC purchased a new stake in shares of Sotera Health during the third quarter valued at about $57,000. Finally, CWM LLC lifted its position in shares of Sotera Health by 194.6% during the third quarter. CWM LLC now owns 5,191 shares of the company’s stock valued at $82,000 after buying an additional 3,429 shares during the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $15.27, for a total value of $152,700,000.00. Following the transaction, the director owned 12,735,301 shares in the company, valued at approximately $194,468,046.27. This represents a 43.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 15.36% of the company’s stock.

Sotera Health Stock Performance

Shares of Sotera Health stock opened at $15.63 on Wednesday. The firm has a market capitalization of $4.46 billion, a P/E ratio of 38.12 and a beta of 1.82. The company has a quick ratio of 2.54, a current ratio of 2.82 and a debt-to-equity ratio of 3.56. The company has a 50 day moving average price of $14.90 and a 200 day moving average price of $16.46. Sotera Health Company has a 52 week low of $10.80 and a 52 week high of $19.85.

Sotera Health (NASDAQ:SHCGet Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.01. Sotera Health had a net margin of 9.91% and a return on equity of 39.73%. The company had revenue of $280.05 million for the quarter, compared to the consensus estimate of $270.78 million. During the same quarter in the prior year, the company earned $0.14 EPS. Sotera Health’s quarterly revenue was up 10.0% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.930-1.010 EPS. Sell-side analysts expect that Sotera Health Company will post 0.88 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on SHC. Citigroup increased their price target on shares of Sotera Health from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Barclays decreased their price target on shares of Sotera Health from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Zacks Research lowered shares of Sotera Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Piper Sandler reissued an “overweight” rating and set a $22.00 price target (down from $24.00) on shares of Sotera Health in a research report on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of Sotera Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Sotera Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Check Out Our Latest Research Report on SHC

About Sotera Health

(Free Report)

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

Read More

Institutional Ownership by Quarter for Sotera Health (NASDAQ:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.